Literature DB >> 2159538

Serum-neutralizing antibody to VP4 and VP7 proteins in infants following vaccination with WC3 bovine rotavirus.

R L Ward1, D R Knowlton, H B Greenberg, G M Schiff, D I Bernstein.   

Abstract

Serum specimens from infants 2 to 12 months old vaccinated with the WC3 bovine rotavirus were analyzed to determine the relative concentrations of neutralizing antibody to the VP4 and VP7 proteins of the vaccine virus. To do this, reassortant rotaviruses that contained the WC3 genome segment for only one of these two neutralization proteins were made. The segment for the other neutralization protein in these reassortants was from heterotypic rotaviruses that were serotypically distinct from WC3. Sera were examined from 31 infants who had no evidence of a previous rotavirus infection and the highest postvaccination WC3-neutralizing antibody titers (i.e., 160 to 600) of the 103 subjects administered the vaccine. A reassortant (3/17) that contained both neutralization proteins from the heterotypic rotaviruses, i.e., EDIM (EW strain of mouse rotavirus) VP7 and rhesus rotavirus VP4, was not neutralized by these sera (geometric mean titer [GMT], less than 20). A reassortant (E19) that contained EDIM VP7 and WC3 VP4 was also very poorly neutralized by these antisera (GMT = 20). In contrast, antibody titers to a reassortant (R20) that contained WC3 VP7 and rhesus rotavirus VP4 were higher than those against WC3 (GMTs of 458 and 313, respectively). Thus, VP7 appeared to be the dominant immunogen for production of neutralizing antibody after intestinal infection of previously uninfected infants vaccinated with WC3 bovine rotavirus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2159538      PMCID: PMC249447          DOI: 10.1128/JVI.64.6.2687-2691.1990

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Epitope-specific immune responses to rotavirus vaccination.

Authors:  R D Shaw; K J Fong; G A Losonsky; M M Levine; Y Maldonado; R Yolken; J Flores; A Z Kapikian; P T Vo; H B Greenberg
Journal:  Gastroenterology       Date:  1987-11       Impact factor: 22.682

2.  Genes of human (strain Wa) and bovine (strain UK) rotaviruses that code for neutralization and subgroup antigens.

Authors:  A R Kalica; H B Greenberg; R G Wyatt; J Flores; M M Sereno; A Z Kapikian; R M Chanock
Journal:  Virology       Date:  1981-07-30       Impact factor: 3.616

3.  Gene coding assignments for growth restriction, neutralization and subgroup specificities of the W and DS-1 strains of human rotavirus.

Authors:  H B Greenberg; J Flores; A R Kalica; R G Wyatt; R Jones
Journal:  J Gen Virol       Date:  1983-02       Impact factor: 3.891

4.  Antigenic comparisons of two new rotaviruses from rhesus monkeys.

Authors:  G Stuker; L S Oshiro; N J Schmidt
Journal:  J Clin Microbiol       Date:  1980-02       Impact factor: 5.948

5.  Immune response to rotavirus polypeptides after vaccination with heterologous rotavirus vaccines (RIT 4237, RRV-1).

Authors:  L Svensson; H Sheshberadaran; T Vesikari; E Norrby; G Wadell
Journal:  J Gen Virol       Date:  1987-07       Impact factor: 3.891

6.  Human rotavirus studies in volunteers: determination of infectious dose and serological response to infection.

Authors:  R L Ward; D I Bernstein; E C Young; J R Sherwood; D R Knowlton; G M Schiff
Journal:  J Infect Dis       Date:  1986-11       Impact factor: 5.226

7.  Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to the heterotypic neutralization domain of VP7 and the VP8 fragment of VP4.

Authors:  S M Matsui; P A Offit; P T Vo; E R Mackow; D A Benfield; R D Shaw; L Padilla-Noriega; H B Greenberg
Journal:  J Clin Microbiol       Date:  1989-04       Impact factor: 5.948

8.  Susceptibility of mice to rotavirus infection: effects of age and administration of corticosteroids.

Authors:  J L Wolf; G Cukor; N R Blacklow; R Dambrauskas; J S Trier
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

9.  Analysis by plaque reduction neutralization assay of intertypic rotaviruses suggests that gene reassortment occurs in vivo.

Authors:  Y Hoshino; M M Sereno; K Midthun; J Flores; R M Chanock; A Z Kapikian
Journal:  J Clin Microbiol       Date:  1987-02       Impact factor: 5.948

10.  Antigenic mapping of the surface proteins of rhesus rotavirus.

Authors:  R D Shaw; P T Vo; P A Offit; B S Coulson; H B Greenberg
Journal:  Virology       Date:  1986-12       Impact factor: 3.616

View more
  12 in total

1.  Homotypic and heterotypic serological responses to rotavirus neutralization epitopes in immunologically naive and experienced animals.

Authors:  D R Snodgrass; T A Fitzgerald; I Campbell; G F Browning; F M Scott; Y Hoshino; R C Davies
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

2.  Neutralizing antibodies to heterologous animal rotavirus serotypes 5, 6, 7, and 10 in sera from Ecuadorian children.

Authors:  H Brüssow; P A Offit; J Sidoti
Journal:  J Clin Microbiol       Date:  1991-05       Impact factor: 5.948

3.  Production of reassortant viruses containing human rotavirus VP4 and SA11 VP7 for measuring neutralizing antibody following natural infection.

Authors:  R J Gorrell; R F Bishop
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

4.  Serotype specificity of the neutralizing-antibody response induced by the individual surface proteins of rotavirus in natural infections of young children.

Authors:  G Menchaca; L Padilla-Noriega; M Méndez-Toss; J F Contreras; F I Puerto; H Guiscafré; F Mota; I Herrera; R Cedillo; O Muñoz; R Ward; Y Hoshino; S López; C F Arias
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

5.  Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles.

Authors:  S E Crawford; M K Estes; M Ciarlet; C Barone; C M O'Neal; J Cohen; M E Conner
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

6.  VP4-specific intestinal antibody response to rotavirus in a murine model of heterotypic infection.

Authors:  R D Shaw; W S Groene; E R Mackow; A A Merchant; E H Cheng
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

7.  Humoral immune responses to VP4 and its cleavage products VP5* and VP8* in infants vaccinated with rhesus rotavirus.

Authors:  L Padilla-Noriega; L Fiore; M B Rennels; G A Losonsky; E R Mackow; H B Greenberg
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

8.  Rotavirus-specific intestinal immune response in mice assessed by enzyme-linked immunospot assay and intestinal fragment culture.

Authors:  C A Khoury; K A Brown; J E Kim; P A Offit
Journal:  Clin Diagn Lab Immunol       Date:  1994-11

9.  Immunodominance of the VP4 neutralization protein of rotavirus in protective natural infections of young children.

Authors:  R L Ward; M M McNeal; D S Sander; H B Greenberg; D I Bernstein
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

10.  Prevalence of neutralizing antibodies against different rotavirus serotypes in children with severe rotavirus-induced diarrhea and their mothers.

Authors:  Pratibha G Ray; Shobhana D Kelkar
Journal:  Clin Diagn Lab Immunol       Date:  2004-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.